Inhaled glucocorticoids: Influence on bone mineral density and bone metabolism;Influencia de los glucocorticoides inhalados sobre la densidad mineral osea y el metabolismo oseo

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 7, Issue 4, 2000, Pages 211-218

  Saraví, Fernando D ^a,b   Guirao, Manuel A ^a   Elías, P Carlos ^b,c   Guarnieri, Pablo J ^b  

^a Escuela de Medicina Nuclear   (Argentina)

^b UNIVERSIDAD NACIONAL DE CUYO   (Argentina)

^c Fundacion Escuela de Med Nuclear   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE; BUDESONIDE; CALCIUM; FLUTICASONE; GLUCOCORTICOID; VITAMIN D;

ADULT; ARTICLE; ASTHMA; BONE DENSITY; BONE GROWTH; BONE METABOLISM; BONE MINERAL; CORTICOSTEROID THERAPY; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; GROWTH DISORDER; HORMONE SUBSTITUTION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; POSTMENOPAUSE; PRESCHOOL CHILD;

EID: 0034120911     PISSN: 10204989     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1020-49892000000400001     Document Type: Article

References (122)

1. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 1996;14:199-206.
2. Sambrook PN. Corticosteroid induced osteoporosis. J Rheumatol 1996;23(supl 45):S19-S22.
3. Adachi JD. Corticosteroid-induced osteoporosis. Am J Med Sci 1997;313:41-49.
4. Lems WF, Jahangier ZN, Jacobs JWG, Bijlsma JWJ. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin Exp Rheumatol 1995;13: 293-297.
5. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995; 22:1055-1059.
6. Dequeker J, Westhovens R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention [Editorial]. J Rheumatol 1995;22:1013-1019.
7. Saito JK, Davis JW, Wasnich RD, Ross PD. Users of low-dose glucocorticoids have increased bone loss rates: a longitudinal study. Calcif Tissue Int 1995;57:115-119.
8. Laan RFJM, van Riel PLCM, van de Putte LBA, van Erning LJTO, van't Hof MA, Lemmens JAM. Low-dose prednisolone induces rapid reversible axial bone loss in patients with rheumatoid arthritis: a randomized, controlled study. Ann Intern Med 1993;119: 963-968.
9. Peel N, Eastell R. ABC of rheumatology: osteoporosis. BMJ 1995;310:989-992.
10. National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis. Washington: National Osteoporosis Foundation; 1998.
11. Melton LJ III, Thamer M, Ray NF, Chan JK, Chesnut CH III, Einhorn TA, et al. Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:16-23.
12. Melton LJ. Global aspects of osteoporosis epidemiology. En: Papapoulos SE, Lips P, Pols HAP, Johnston CC, Delmas PD, eds. Osteoporosis 1996. Amsterdam: Elsevier; 1996; 79-86.
13. Canalis E. Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis. J Clin Endocrinol Metab 1996;81:3441-3447.
14. Adler RA. Preventing and treating glucocorticoid osteoporosis. En: Rosen CJ, ed. Osteoporosis: diagnostic and therapeutic principles. Totowa: Humana Press; 1996:239-249.
15. Eastell R. Management of corticosteroid-induced osteoporosis: UK Consensus Group Meeting on Osteoporosis. J Intern Med 1995; 237:439-447.
16. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Eng J Med 1983;309:265-268.
17. Lane SJ, Vaja S, Swaminathan R, Lee TH. Effects of prednisolone on bone turnover in patients with corticosteroid resistant asthma. Clin Exp Allergy 1996;26:1197-1201.
18. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 1996; 313:344-346.
19. Expert Panel Report 2. Guidelines for the diagnosis and management of asthma. Washington: National Institutes of Health; 1997. (Publication 97-4051).
20. Barnes PJ. Inhaled glucocorticoids for asthma. N Eng J Med 1995;332:868-875.
21. Barnes PJ. Corticosteroids. En: O'Byrne PM, Thomson NC, eds. Manual of asthma. London: W.B. Saunders; 1995:219-253.
22. Cockcroft DW, Kalra S. Outpatient asthma management. Med Clin North Am 1996;80: 701-718.
23. Wihl JA, Andersson KE, Johansson SA. Systemic effects of two nasally administered glucocorticosteroids. Allergy 1997;52:620-626.
24. Grahnen A, Jansson B, Brundin RM, Ling-Andersson A, Lonnebo A, Johansson M, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler. Eur J Clin Pharmacol 1997;52:261-267.
25. Pedersen S, Fuglsang G. Urine cortisol excretion in children treated with high doses of inhaled corticosteroids: a comparison of budesonide and beclomethasone. Eur Respir J 1988;1:433-435.
26. Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-208.
27. Ahmann AJ. Endocrine-metabolic effects of asthma treatment. Immunol Allergy Clin North Am 1997;17:701-726.
28. Barnes N. Relative safety and efficacy of inhaled corticosteroids. J Allergy Clin Immunol 1998;101:S460-S464.
29. Lipsworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. Arch Intern Med 1999;159:941-955.
30. Toogood JH. High-dose inhaled steroid therapy for asthma. J Allergy Clin Immunol 1989;83:528-536.
31. Wagener JS, Wojtczack HA. Inhaled steroids in children: Risks versus rewards [Editorial]. J Pediatr 1998;132:381-383.
32. Wahner HW, Fogelman I. The evaluation of osteoporosis: dual energy X-ray absorptiometry in clinical practice. London: Martin Dunitz; 1994.
33. Swedish Council on Technology Assessment in Health Care. Bone density measurement. A systematic review. J Intern Med 1997; 241(supl 739):12-22.
34. Miller PD, McClung M. Prediction of fracture risk. I: Bone density. Am J Med Sci 1996; 312:257-259.
35. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254-1259.
36. Calvo MS, Eyre DR, Gundberg CM. Molecular basis and clinical applications of biological markers of bone turnover. Endocr Rev 1996;17:333-368.
37. Garnero P, Delmas PD. Les marqueurs biochimiques du remodelage osseux: application a l'exploration de ostéoporoses. Ann Biol Clin (Paris) 1999;57:137-148.
38. Hedlin G, Svedmyr J, Ryden AC. Systemic effects of a short course of bethametasone compared with high-dose inhaled budesonide in early childhood asthma. Acta Paediatr 1999;88:48-51.
39. Wolthers OD, Riis BJ, Pedersen S. Bone turnover in asthmatic children treated with oral prednisolone or inhaled budesonide. Pediatr Pulmonol 1993;16:341-346.
40. Bootsma GP, Dekhuijzen PN, Festen J, Mulder PG, Swinkels LM, van Herwaarden CL. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996;153:924-930.
41. Birkebaek NH, Esberg G, Andersen K, Wolthers O, Hassager C. Bone and collagen turnover during treatment with inhaled dry powder budesonide and beclomethasone dipropionate. Arch Dis Child 1995;73:524-527.
42. König P, Hillman L, Cervantes C, Levine C, Maloney C, Douglass B, et al. Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr 1993;122:219-226.
43. Sorva R, Turpeinen M, Juntunen-Backman K, Karonen SL, Sorva A. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1992;90:808-815.
44. Sorva R, Tähtela R, Turpeinen M, Juntunen-Backman K, Haahtela T, Risteli L, et al. Changes in bone markers in children with asthma during inhaled budesonide and nedocromil treatments. Acta Paediatr 1996; 85:1176-1180.
45. Crowley S, Trivedi P, Risteli L, Risteli J, Hindmarsh PC, Brook CG. Collagen metabolism and growth in prepubertal children with asthma treated with inhaled steroids. J Pediatr 1998;132:409-413.
46. Kinberg KA, Hopp RJ, Biven RE, Gallagher GC. Bone mineral density in normal and asthmatic children. J Allergy Clin Immunol 1994;94:490-497.
47. Baraldi E, Bollini MC, De Marchi A, Zacchello F. Effect of beclomethasone dipropionate on bone mineral content assessed by X-ray densitometry in asthmatic children: a longitudinal evaluation. Eur Respir J 1994; 7:710-714.
48. Hopp RJ, Degan JA, Phelan J, Lappe J, Gallagher GC. Cross-sectional study of bone density in asthmatic children. Pediatr Pulmonol 1995;20:189-192.
49. Martinati LC, Bertoldo F, Gasperi E, Micelli S, Boner AL. Effect on cortical and trabecular bone mass of different antiinflammatory treatments in preadolescent children with chronic asthma. Am J Respir Crit Care Med 1996;153:232-236.
50. Hopp RJ, Degan JA, Biven RE, Kinberg K, Gallagher GC. Longitudinal assessment of bone mineral density in children with chronic asthma. Ann Allergy Asthma Immunol 1995; 75:143-148.
51. Martinati LC, Bertoldo F, Gasperi E, Forrunati P, Lo Cascio V, Boner AL. Longitudinal evaluation of bone mass in asthmatic children treated with inhaled beclomethasone dipropionate or cromolyn sodium. Allergy 1998;53:705-708.
52. Gregson RK, Rao R, Murrills AJ, Taylor PA, Warner JO. Effect of inhaled corticosteroids on bone mineral density in childhood asthma: comparison of fluticasone propionate with beclomethasone dipropionate. Osteoporos Int 1998;8:418-422.
53. Chay OM, Goh A, Lim WH, Leong KH, Lou J. Effects of inhaled corticosteroid on bone turnover in children with bronchial asthma. Respirology 1999;4:63-67.
54. Boot AM, de Jongste JC, Verberne AA, Pols HA, de Muinck Keizer-Schrama SM. Bone mineral density and bone metabolism of prepubertal children with asthma after long-term treatment with inhaled corticosteroids. Pediatr Pulmonol 1997;24:379-384.
55. Agertoft L, Pedersen S. Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. Am J Respir Crit Care Med 1998;157:178-183.
56. Balfour-Lynn L. Growth and childhood asthma. Arch Dis Child 1986;61:1049-1055.
57. Ninan TK, Russell G. Asthma, inhaled corticosteroid treatment, and growth. Arch Dis Child 1992;67:703-705.
58. Allen DB, Mullen M, Mullen B. A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J Allergy Clin Immunol 1994;93:967-976.
59. Saha MT, Laippala P, Lenko HL. Growth of asthmatic children is slower during than before treatment with inhaled glucocorticoids. Acta Paediatr 1997;86:138-142.
60. McCowan C, Neville RG, Thomas GE, Crombie IK, Clark RA, Ricketts JW, et al. Effect of asthma and its treatment on growth: four year follow up of cohort of children from general practices in Tayside, Scotland. BMJ 1998;316:668-672.
61. Nassif E, Weinberger M, Sherman B, Brown K. Extrapulmonary effects of maintenance corticosteroid therapy with alternate-day prednisone and inhaled beclomethasone in children with chronic asthma. J Allergy Clin Immunol 1987;80:518-529.
62. Littlewood JM, Johnson AW, Edwards PA, Littlewood AE. Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet 1988;1 (8577):115-116.
63. Tinkelman DG, Reed CE, Nelson HS, Offord KP. Aerosol beclomethasone dipropionate compared with theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics 1993;92: 64-77.
64. Doull I, Freezer N, Holgate S. Osteocalcin, growth, and inhaled corticosteroids: a prospective study. Arch Dis Child 1996;74: 497-501.
65. Simons FER. A comparison of beclomethasone, salmeterol and placebo in children with asthma. N Eng J Med 1997;337:1659-1665.
66. Veberne AAPH, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One-year treatment with salmeterol compared with beclomethasone in children with asthma. The Dutch Paediatric Asthma Study Group. Am J Respir Crit Care Med 1997;156:688-695.
67. Crowley S, Hindmarsh PC, Matthews DR, Brook CG. Growth and the growth hormone axis in prepubertal children with asthma. J Pediatr 1995;126:297-303.
68. Agertoft L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med 1994;88:373-381.
69. Merkus PJ, van Essen-Zandvliet EE, Duiverman EJ, van Houwelingen HC, Kerrebijn KF, Quanjer PH. Long-term effect of inhaled corticosteroids on growth rate in adolescents with asthma. Pediatrics 1993;91:1121-1126.
70. Price JF, Russel G, Hindmarsh PC, Weller P, Heaf DP, Williams J. Growth during one year of treatment with fluticasone propionate or sodium cromoglycate in children with asthma. Pediatr Pulmonol 1997;24:178-186.
71. Allen DB, Bronsky EA, LaForce CF, Nathan RA, Tinkelman DG, Vandewalker ML, et al. Growth in asthmatic children treated with fluticasone propionate. J Pediatr 1998;132: 472-477.
72. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996;348:27-29.
73. Silverstein MD, Yungiger JW, Reed CE, Petterson T, Zimmerman D, Li JT, et al. Attained adult height after childhood asthma: effect of glucocorticoid therapy. J Allergy Clin Immunol 1997;99:466-474.
74. Food and Drug Administration. Class labeling for intranasal and orally administered corticosteroid containing drug products regarding the potential for growth suppression in children. [Sitio en Internet] FDA Talk Paper. Disponible en: http://www.fda.gov/cder/ news/cs-label.htm. Acceso el 8 marzo, 2000.
75. Jennings BH, Anderson KE, Johansson SA. Assessment of systemic effects of inhaled glucocorticosteroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40:77-82.
76. Teelucksingh S, Padfield PL, Tibi L, Gough KJ, Holt PR. Inhaled corticosteroids, bone formation, and osteocalcin. Lancet 1991;338: 60-61.
77. Toogood JH, Jennings B, Hodsman AB, Baskerville J, Fraher LJ. Effects of dose and dosing schedule of inhaled budesonide on bone turnover. J Allergy Clin Immunol 1991; 88:572-580.
78. Pouw EM, Prummel MF, Costing H, Roos CM, Endert E. Beclomethasone inhalation decreases serum osteocalcin concentrations. BMJ 1991;302:627-628.
79. Meeran K, Hattersley A, Burrin J, Shiner R, Ibbertson K. Oral and inhaled corticosteroids reduce bone formation as shown by plasma osteocalcin levels. Am J Resp Crit Care Med 1995;151:333-336.
80. Hodsman AB, Toogood JH, Jennings B, Fraher LJ, Baskerville JC. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991;72:530-540.
81. Brown PH, Matusiewicz SP, Shearing C, Tibi L, Greening AP, Crompton GK. Systemic effects of high dose inhaled steroids: comparison of beclomethasone dipropionate and budesonide in healthy subjects. Thorax 1993;48:967-973.
82. Ali NJ, Capewell S, Ward MJ. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991;46:160-164.
83. Toogood JH, Crilly RG, Jones G, Nadeau J, Wells GA. Effect of high dose inhaled budesonide on calcium and phosphate metabolism and the risk of osteoporosis. Am Rev Respir Dis 1988;138:57-61.
84. Luengo M, Picado C, Piera C, Guanabens N, Montserrat JM, Rivera J, et al. Intestinal calcium absorption and parathyroid hormone secretion in asthmatic patients on prolonged oral or inhaled steroid treatment. Eur Respir J 1991;4:441-444.
85. Puolijoki H, Lippo K, Herrala J, Salmi J, Tala E. Inhaled beclomethasone decreases serum osteocalcin in postmenopausal asthmatic women. Bone 1992;13:285-288.
86. Leech JA, Hodder RV, Ooi DS, Gay J. Effects of short-term inhaled budesonide and beclomethasone dipropionate on serum osteocalcin in premenopausal women. Am Rev Respir Dis 1993;148:113-115.
87. Kerstjens HA, Postma DS, van Doormaal JJ, van Zanten AK, Brand PL, Dekhuijzen PN, et al. Effects of short-term and long-term treatment with inhaled corticosteroids on bone metabolism in patients with airways obstruction. Dutch CNSLD Study Group. Thorax 1994;49:652-656.
88. Bootsma GP, Dekhuijzen PN, Festen J, Mulder PG, Swinkels LM, van Herwaarden CL. Fluticasone propionate does not influence bone metabolism in contrast to beclomethasone dipropionate. Am J Respir Crit Care Med 1996;153:924-930.
89. Malo JL, Cartier A, Ghezzo H, Mark S, Brown J, Laviolette M, et al. Skin bruising, adrenal function and markers of bone metabolism in asthmatics using inhaled beclomethasone and fluticasone. Eur Respir J 1999;13:993-998.
90. Lipworth BJ, Clark DJ. High dose inhaled steroids in asthmatic children [Carta]. Lancet 1996;348:820.
91. Haapasaari K, Rossi O, Risteli J, Oikarinen A, Effects of long-term inhaled corticosteroids on skin collagen synthesis and thickness in asthmatic patients. Eur Respir J 1998;11: 139-143.
92. Wolff AH, Adelsberg B, Aloia J, Zitt M. Effect of inhaled corticosteroid on bone density in asthmatic patients: a pilot study. Ann Allergy 1991;61:117-121.
93. Luengo M, Del Río L, Guanabens N, Picado C. Long-term effect of oral and inhaled glucocorticoids on bone mass in chronic asthma. A two year follow-up study. Eur Respir J 1991;4 (supl 14):S342.
94. Herrala J, Puolijoki H, Impivaara O, Liippo K, Tala E, Nieminen MM. Bone mineral density in asthmatic women on high-dose inhaled beclomethasone dipropionate. Bone 1994;15:621-623.
95. Luengo M, del Rio L, Pons F, Picado C. Bone mineral density in asthmatic patients treated with inhaled corticosteroids: a case-control study. Eur Respir J 1997;10:2110-2113.
96. Gagnon L, Boulet LP, Brown J, Desrosiers T. Influence of inhaled corticosteroids and dietary intake on bone density and metabolism in patients with moderate to severe asthma. J Am Diet Assoc 1997;97:1401-1406.
97. Boulet LP, Giguere MC, Milot J, Brown J. Effects of long-term use of high-dose inhaled steroids on bone density and calcium metabolism. J Allergy Clin Immunol 1994;94:796-803.
98. Hughes JA, Conry BG, Male SM, Eastell R. One year prospective open study of the effect of high dose inhaled steroids, fluticasone propionate, and budesonide on bone markers and bone mineral density. Thorax 1999; 54:223-229.
99. Wisniewski AF, Lewis SA, Green DJ, Maslanka W, Burrell H, Tattersfield AE. Cross sectional investigation of the effects of inhaled corticosteroids on bone density and bone metabolism in patients with asthma. Thorax 1997;52:853-860.
100. Boulet LP, Milot J, Gagnon L, Poubelle PE, Brown J. Long-term influence of inhaled corticosteroids on bone metabolism and density. Are biological markers predictors of bone loss? Am J Respir Crit Care Med 1999; 159: 838-844.
101. Howland WC III. Fluticasone dipropionate: topical or systemic effects? Clin Exp Allergy 1996;26(supl 3):18-22.
102. Li JT, Ford LB, Chervinsky P, Weisberg SC, Kellerman DJ, Faulkner KG, et al. Fluticasone propionate powder and lack of clinically significant effects on hypothalamic-pituitary-adrenal axis and bone mineral density over 2 years in adults with mild asthma. J Allergy Clin Immunol 1999;103:1062-1068.
103. Pauwels RA, Yernault JC, Demedts MG, Geusens P. Safety and efficacy of fluticasone and beclomethasone in moderate to severe asthma. Belgian Multicenter Study Group. Am J Respir Crit Care Med 1998;157:827-832.
104. Packe GE, Douglas JG, McDonald AF, Robins SP, Reid DM. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systemic corticosteroids. Thorax 1992;47: 414-417.
105. Packe GE, Robb O, Robins SP, Reid DM, Douglas JG. Bone density in asthmatic patients taking inhaled corticosteroids: comparison of budesonide and beclomethasone dipropionate. J R Coll Phys Lond 1996;30: 128-132.
106. Laroche M, Porteau L, Caron P, Moulinier L, Didier A, Amigues JM, et al. Osteovertebral fractures in a man under high-dose inhaled glucocorticoid therapy. Rev Rhum Eng Ed 1997;64:267-270.
107. Marystone JF, Barrett-Connor EL, Morton DJ. Inhaled and oral corticosteroids: their effects on bone mineral density in older adults. Am J Public Health 1995;85:1693-1695.
108. Lau EM, Li M, Woo J, Lai C. Bone mineral density and body composition in patients with airflow obstruction - the role of inhaled steroid therapy, disease and lifestyle. Clin Exp Allergy 1998;28:1066-1071.
109. Ip M, Lam K, Yam L, Kung A, Ng M. Decreased bone mineral density in premenopausal asthma patients receiving long-term inhaled steroids. Chest 1994;105:1722-1727.
110. Toogood JH, Baskerville JC, Markov AE, Hodsman AB, Fraher LJ, Jennings B, et al. Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma. J Allergy Clin Immunol 1995;96:157-166.
111. Ebeling PR, Erbas B, Hopper JL, Wark JD, Rubinfeld AR. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res 1998;13:1283-1289.
112. Hanania NA, Chapman KR, Sturtridge WC, Szalai JP, Kesten S. Dose-related decrease in bone density among asthmatic patients treated with inhaled corticosteroids. J Allergy Clin Immunol 1995;96:571-579.
113. Struijs A, Mulder H. The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. Neth J Med 197;50:233-237.
114. Egan JJ, Maden C, Kalra S, Adams JE, Eastell R, Woodcock AA. A randomized, double-blind study comparing the effects of beclomethasone and fluticasone on bone density over two years. Eur Respir J 1999;13: 1267-1275.
115. Wang WQ, Ip MS, Tsang KW, Lam KS. Antiresorptive therapy in asthmatic patients receiving high-dose inhaled steroids: a prospective study for 18 months. J Allergy Clin Immunol 1998;101:445-450.
116. Jackson LD, Polygenis D, McIvor RA, Worthington I. Comparative efficacy and safety of inhaled corticosteroids in asthma. Can J Clin Pharmacol 1999;6:26-37.
117. Li JTC, Reed CE. Proper use of aerosol corticosteroids to control asthma. Mayo Clin Proc 1989;64:205-210.
118. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose inhaled corticosteroids? Thorax 1990;45:736-739.
119. Selroos O, Halme M. Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler. Thorax 1991;46:891-894.
120. 3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-968.
121. Martin AD, Bailey DA, McKay HA, Whiting S. Bone mineral and calcium accretion during puberty. Am J Clin Nutr 1997;66:611-615.
122. Duplantier AJ, Turner CR. Novel pharmacological approaches to the treatment of asthma: status and potential of therapeutic classes. Drug Discov Today 1996;1:199-208.